Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral EB612 versus subcutaneous Natpara pharmacokinetic/pharmacodynamic study in adults with hypoparathyroidism
MOH_2018-05-10_002301Phase 2Not yet recruiting
- Sponsor
- Entera Bio Ltd.
- Start
- May 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of EBP11 and parathyroid hormone 1-84 in hypoparathyroidism (3 arms), sponsored by Entera Bio Ltd. Primary endpoints: Pharmacokinetics of EB612 and Natpara and Pharmacodynamics on calcium and metabolic markers. Planned start May 2018; status: not yet recruiting.
02
Drugs
EBP11parathyroid hormone 1-84
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on MOH_2018-05-10_002301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-10_002301.